Catechol-O-methyltransferase inhibitors

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The introduction of levodopa therapy for Parkinson’s disease (PD), initially by Birkmayer et al. (1) in 1961, followed by Barbeau et al. (2) in 1962, and in its ultimately successful form by Cotzias et al. (3) in 1967, still represents the defining landmark in the treatment of PD. This dramatic advance did not materialize out of thin air. It was preceded by methodical basic laboratory research in the late 1950s and early 1960s, which formed a groundwork documenting the presence of striatal dopamine deficiency in PD (4-8) and paved the road for the application of this knowledge in the clinical arena.

Original languageEnglish (US)
Title of host publicationHandbook of Parkinson's Disease, Fifth Edition
PublisherCRC Press
Pages448-465
Number of pages18
ISBN (Electronic)9781841849096
ISBN (Print)9781841849089
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Parkinson Disease
Corpus Striatum
Levodopa
Dopamine
Research
Catechol O-Methyltransferase Inhibitors
Therapeutics
Parkinson Disease 8

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pfeiffer, R. (2013). Catechol-O-methyltransferase inhibitors. In Handbook of Parkinson's Disease, Fifth Edition (pp. 448-465). CRC Press.

Catechol-O-methyltransferase inhibitors. / Pfeiffer, Ronald.

Handbook of Parkinson's Disease, Fifth Edition. CRC Press, 2013. p. 448-465.

Research output: Chapter in Book/Report/Conference proceedingChapter

Pfeiffer, R 2013, Catechol-O-methyltransferase inhibitors. in Handbook of Parkinson's Disease, Fifth Edition. CRC Press, pp. 448-465.
Pfeiffer R. Catechol-O-methyltransferase inhibitors. In Handbook of Parkinson's Disease, Fifth Edition. CRC Press. 2013. p. 448-465
Pfeiffer, Ronald. / Catechol-O-methyltransferase inhibitors. Handbook of Parkinson's Disease, Fifth Edition. CRC Press, 2013. pp. 448-465
@inbook{8226e9afae794a55b5b0898abb7cda9f,
title = "Catechol-O-methyltransferase inhibitors",
abstract = "The introduction of levodopa therapy for Parkinson’s disease (PD), initially by Birkmayer et al. (1) in 1961, followed by Barbeau et al. (2) in 1962, and in its ultimately successful form by Cotzias et al. (3) in 1967, still represents the defining landmark in the treatment of PD. This dramatic advance did not materialize out of thin air. It was preceded by methodical basic laboratory research in the late 1950s and early 1960s, which formed a groundwork documenting the presence of striatal dopamine deficiency in PD (4-8) and paved the road for the application of this knowledge in the clinical arena.",
author = "Ronald Pfeiffer",
year = "2013",
month = "1",
day = "1",
language = "English (US)",
isbn = "9781841849089",
pages = "448--465",
booktitle = "Handbook of Parkinson's Disease, Fifth Edition",
publisher = "CRC Press",

}

TY - CHAP

T1 - Catechol-O-methyltransferase inhibitors

AU - Pfeiffer, Ronald

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The introduction of levodopa therapy for Parkinson’s disease (PD), initially by Birkmayer et al. (1) in 1961, followed by Barbeau et al. (2) in 1962, and in its ultimately successful form by Cotzias et al. (3) in 1967, still represents the defining landmark in the treatment of PD. This dramatic advance did not materialize out of thin air. It was preceded by methodical basic laboratory research in the late 1950s and early 1960s, which formed a groundwork documenting the presence of striatal dopamine deficiency in PD (4-8) and paved the road for the application of this knowledge in the clinical arena.

AB - The introduction of levodopa therapy for Parkinson’s disease (PD), initially by Birkmayer et al. (1) in 1961, followed by Barbeau et al. (2) in 1962, and in its ultimately successful form by Cotzias et al. (3) in 1967, still represents the defining landmark in the treatment of PD. This dramatic advance did not materialize out of thin air. It was preceded by methodical basic laboratory research in the late 1950s and early 1960s, which formed a groundwork documenting the presence of striatal dopamine deficiency in PD (4-8) and paved the road for the application of this knowledge in the clinical arena.

UR - http://www.scopus.com/inward/record.url?scp=85054761473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054761473&partnerID=8YFLogxK

M3 - Chapter

SN - 9781841849089

SP - 448

EP - 465

BT - Handbook of Parkinson's Disease, Fifth Edition

PB - CRC Press

ER -